The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries. About HistogenHistogen Inc. is a clinical-stage ...

Many of the development activities leading up to the submission of an Investigational New Drug Application (IND ... and is frequently the cause of filing delays or worse. Based on experience ...

has cleared the Investigational New Drug (IND) application for DTX401, an adeno-associated virus vector based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).

NCP remains a major unmet medical need for the ocular community, as there is no FDA-approved drug to treat NCP and this trial provides the opportunity to establish OK-101’s potential to treat ...

OCEANSIDE, Calif.--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. announced today filing of an Investigational New Drug (IND) application with the United States Food and Drug ...

has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone ...

YARDLEY, Pa.--(BUSINESS WIRE)-- OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011.The FDA has completed its ...

April 23 (Reuters) - Ultragenyx Pharmaceutical Inc: * ULTRAGENYX ANNOUNCES FILING AND FDA CLEARANCE OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR DTX401, A GENE THERAPY FOR THE TREATMENT OF ...

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application ... The IND filing represents a major step ...

The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries. About Histogen Histogen Inc. is a clinical-stage ...

NCP remains a major unmet medical need for the ocular community, as there is no FDA-approved drug to treat NCP and this trial provides the opportunity to establish OK-101’s potential to treat ...